Eton Pharmaceuticals, Inc. Common Stock (ETON) Stock
NASDAQ · ETON
57.09
Fundamentals
Market cap
$1.58B
Price / Earnings ratio
124.6x
Price / Sales ratio
15.0x
Price / Book ratio
33.9x
Return on assets
-0.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Eton Pharmaceuticals, Inc. Common Stock
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees44
CEOMr. Sean E. Brynjelsen
IPO DateNov 9, 2018
HeadquartersDeer Park, IL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean E. Brynjelsen | President, CEO & Director | 1972 |
| Mr. David C. Krempa | Chief Business Officer | 1989 |
| Mr. James R. Gruber CPA | Consultant | 1972 |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer | 1982 |
| Ms. Judith M. Matthews | Chief Financial Officer & Secretary | 1970 |
| Ms. Danka Radosavljevic | Chief Operating Officer | 1984 |
| Mr. Scott Grossenbach | Senior Vice President of Sales Operations | — |
Fundamentals
Valuation
Market cap$1.58B
Price-to-sales ratio14.97
Price-to-book value33.94
Price-earnings ratio124.60
Return on Equity-6.00%
Return on Sales0.02%
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$0.47
Income Statement
Average volume494,762
EBITDA$6.24M
1 year high (52w)$66.37
1 year low (52w)$14.27
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



